Differential expressions of cyclin D1 associated with better prognosis of cancers of ampulla of vater

World Journal of Surgery

Volumn 31, Issue 5, 2007, Pages 1135-1141

  Chang, Ming Chug ^a   Chang, Yu Ting ^a   Sun, Chia Tung ^a   Chiu, Yen Feng ^b   Lin, Jaw Town ^a   Tien, Yu Wen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; PROTEIN; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE; DEMOGRAPHY; FEMALE; GENE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PANCREAS CANCER; PATHOLOGIST; PATHOLOGY; PROGNOSIS; PROTEIN EXPRESSION; SAMPLING; STAINING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TAIWAN; UNIVERSITY HOSPITAL; VATER PAPILLA CARCINOMA;

AMPULLA OF VATER; CHI-SQUARE DISTRIBUTION; COMMON BILE DUCT NEOPLASMS; CYCLIN D1; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34248182599     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-006-0032-6     Document Type: Article

References (26)

1. Sarmiento JM, Nagomey DM, Sarr MG, et al. Periampullary cancers: are there differences? Surg Clin North Am 2001;81:543-555.
2. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
3. Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 1991;47:148-154.
4. Kim SG, Chan AO, Wu TT, et al. Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas. Gastroenterology 2003;124:1300-1310.
5. Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002;8:3156-3163.
6. Howe JR, Klimstra DS, Cordon-Cardo C, et al. K-ras mutation in adenomas and carcinomas of the ampulla of Vater. Clin Cancer Res 1997;3:129-133.
7. Suto T, Habano W, Sugai T, et al. Infrequent microsatellite instability in biliary tract cancer. J Surg Oncol 2001;76:121-126.
8. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
9. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-1783.
10. Migaldi M, Sgambato A, Garagnani L, et al. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000;6:3131-3138.
11. Alle KM, Henshall SM, Field AS, et al. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998;4:847-854.
12. Yuan J, Knorr J, Altmannsberger M, et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999;189:358-362.
13. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43.
14. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 1998;58:4740-4744.
15. Belvedere O, Puglisi F, Di Loreto C, et al. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann Oncol 2004;15:55-58.
16. Wang CH, Mo LR, Lin RC, et al. A survival predictive model in patients undergoing radical resection of ampullary adenocarcinoma. Hepatogastroenterology 2004;51:1495-1499.
17. Memon MA, Shiwani MH, Anwer S. Carcinoma of the ampulla of Vater: results of surgical treatment of a single center. Hepatogastroenterology 2004;51:1275-1277.
18. de Castro SM, Kuhlmann KF, van Heek NT, et al. Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg 2004;8:775-784; discussion 784.
19. Han S, Park K, Bae BN, et al. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol Rep 2003;10:141-144.
20. Esposito I, Friess H, Buchler MW. Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms. Langenbecks Arch Surg 2001;386:163-171.
21. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-1637.
22. Qiao Q, Ramadani M, Gansauge S, et al. Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 2001;95:194-197.
23. Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89:469-474.
24. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002;20:4531-4542.
25. Yamazaki K, Hanami K, Nagao T, et al. Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear beta catenin accumulation and k-ras gene mutation. Mol Pathol 2003;56:336-341.
26. Liu SC, Zhang SY, Babb JS, et al. Image cytometry of cyclin D1: a prognostic marker for head and neck squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2001;10:455-459.